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A B S T R A C T
The patients treated with conservative surgical therapy for cervical intraepithelial neoplasia (CIN) have an increased
risk to develop invasive cervical carcinoma compared to the general population. Cervical cytology and HPV test are in-
cluded in the protocols for the detection of treatment failure. The purpose of the study was to analyse cytology-histology
correlation after conisation or Large Loop Excision of the Transformation Zone (LLETZ), resection margin status, com-
pliance to the follow-up protocol and evaluation of cervical cytology and HPV testing in two year period after surgical
treatment. We retrospectively reviewed 251 cases of conisation or LLETZ performed between January and December,
2006. Conventional cervical smears were analysed and abnormal cytology was defined as atypical squamous cells of un-
determined significance or worse (ASCUS+). The digene Hybrid capture 2 test was used for detection of high-risk HPV
types. Histology analysis demonstrated CIN1+ lesion in 234 cases (93.2%) with cytology-histology correlation in 97.9%
of cases. A preoperative HPV test was made in 142 histologically confirmed CIN1+ lesions and 137 (96.5%) tested posi-
tive. The resection margins were involved in 48 (20.8%) cases. In 24 (10.3%) cases the margins were difficult to deter-
mine. Abnormal cytology was found in 33 (15.2%) cases of the 217 (86.5%) patients that attended the post-treatment vis-
its. The post-treatment HPV test was performed on 159 women and it was positive in 25 (15.7%) cases. The complete
follow-up control cytology, with at least three Pap smears in the subsequent two years or with second treatment, was reg-
istered in only 146 (58.2%) patients. 14/217 (6.5%) patients underwent second treatment with histologically confirmed
treatment failure. In all patients with control smear, repeated cytology found HSIL. On six women, the control HPV test
was performed. In five cases, it was positive and in one case with histological diagnoses of VAIN2, it was negative. Our
study confirms the important role of cervical cytology in the diagnosis of cervical intraepithelial lesions and monitoring
after treatment. In the future we will have to improve compliance to the follow-up protocols and use of the HPV test in the
selection of women at risk of treatment failure.
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Introduction
The incidence ratio of cervical cancer has decreased in
developed countries during the past few decades due to
cytology based opportunistic or organised screening pro-
grammes for the detection of precancerous lesions. It has
been recognized that persistent infection with high-risk
human papillomavirus (HPV) is necessary for develop-
ment and maintenance of high-grade cervical intraepi-
thelial neoplasia (CIN) and for progression to cervical
cancer1-3. Conservative methods are recommended pro-
cedures for treatment of high-grade CIN especially for
young women. The excisional surgical methods, such as
cold knife conisation or Large Loop Excision of the Trans-
formation Zone (LLETZ) are performed for both diag-
nostic and therapeutic purposes and they provide a speci-
men for histological diagnosis and assessment of the
excisional margins. Several risk factors for treatment
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failure have been analysed, including the positive or un-
certain excision margins, extension of the lesion to the
endocervical glands, satellite lesions of HPV infection lo-
cated outside the transformation zone, patient’s age,
HPV viral load and grade of the lesion. Regardless of the
destructive or excisional surgical treatment of CIN there
is a risk of treatment failure4. A recent meta-analysis and
a retrospective cohort study linking cancer registered
data with treatment history showed that these women
have four to five times an increased risk in developing in-
vasive cervical cancer in the following 10 to 20 years
upon conservative surgical treatment compared to the
general population5,6. This data indicates the necessity of
close surveillance following treatment in order to reduce
the risk of invasive cancer. In medical databases many re-
ports analyse and re-evaluate methods and protocols for
detection of treatment failure in patients treated for
CIN. Most persistent or recurrent diseases are detected
within the first two years after treatment7. Cervical cy-
tology is important in the monitoring of patients after
treatment with limitation of lower sensitivity. With the
introduction of validated HPV testing in clinical practice
the follow-up protocols allow more accurate selection of
those women not at risk for residual or recurrent disease,
from those requiring close surveillance.
The aim of this study was to analyse cytology-histol-
ogy correlation after conisation or LLETZ for cervical
intraepithelial lesions, resection margin status, compli-
ance to the follow-up protocol and evaluation of cervical
cytology and HPV testing in the two year period after
surgical treatment.
Materials and Methods
A retrospective study was made at the Department of
Gynecological Cytology, Department of Gynecology and
Obstetrics, University Hospital Centre Rijeka, Croatia,
where 251 patients underwent conisation (N=141) or
LLETZ (N=110) between January and December 2006.
At the pretreatment visit conventional cervical sme-
ars were collected, analysed and classified according to
the »Zagreb 2002« classification8, a modification of the
2001 Bethesda System9, that was used for cytological
classification. Abnormal cytology was defined as atypical
squamous cells of undetermined significance or worse
(ASCUS+).
Digene Hybrid Capture 2 test was used for detection
of HPV DNA, with cocktail probes for 13 high-risk types
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). Cer-
vical samples were collected with Digene Cervical Sam-
pler and the test was performed following the manufac-
turer’s instructions (QIAGEN, Gaithersburg, USA).
Conisations or LLETZ were performed after abnor-
mal cytology finding was obtained and after colposcopic
examination. The material underwent histological analy-
sis and was classified according to the WHO criteria10.
Preoperative analysis included initial cervical cytol-
ogy and the HPV test. Histological features included
histologic diagnosis with resection margins status and
cytology-histology correlation was assessed as well. Exci-
sion margins were positive when endocervical and/or
ectocervical margins showed dysplasia. In the two year
follow-up period we analysed compliance to the follow-up
protocol, cervical cytology and the HPV test for detection
of treatment failure. The presence of histologically con-
firmed CIN 1+ was considered as treatment failure.
Results
In the one year period out of the 251 patients, 141
were treated by conisation and 110 by LLETZ. The mean
age of the patients was 36.1 years (range 19- 63 years).
The initial cytology included 7 (2.8%) ASCUS, 12
(4.8%) atypical squamous cells- could not exclude HSIL
(ASC-H), 2 (0.8%) low grade squamous intraepithelial le-
sion (LSIL), 189 (75.3%) high grade squamous intraepi-
thelial lesion (HSIL), 17 (6.8%) HSIL-could not exclude
micronivasion, 6 (2.4%) HSIL/CIN3 associated with aty-
pical glandular cells (AGC), 1 (0.4%) adenocarcinoma in
situ (AIS), 2 (0.8%) HSIL/CIN 3 associated with AIS, and
6 (2.4%) carcinomas (in 4 cases cytology indicated a
microinvasive lesion). Of the remaining 9 (3.5%) patients
4 underwent conisation for CIN detected on biopsy, and
in 5 cases the initial cytology was not available. After sur-
gical treatment of 251 patients, histology analysis dem-
onstrated CIN1+ lesion in 234 cases (93.2%). Histology
diagnoses included 13 CIN1, 185 CIN2/3, 2 AIS, 3 CIN3+
AIS, 26 microinvasive carcinomas, 1 microinvasive carci-
noma associated with AIS and 4 invasive carcinomas.
Overall, histology evaluation showed 203 (86.8%) cervi-
cal intraepithelial lesions, 27 microinvasive carcinomas
(11.5%), and 4 invasive carcinomas (1.7%).
In 17 cases (6.7%) of negative histology initial cytol-
ogy finding was ASCUS in 3 cases, ASC-H in 1, HSIL in
9, in 3 cases patients underwent conisation for CIN de-
tected on biopsy, and in 1 case the initial cytology was not
available.
The initial cytology and cytology-histology correlation
are summarised in Table 1.
Comparing initial cytology with histology diagnosis,
cytology-histology correlation for CIN 1+ was found in
97.9% of cases, and for CIN 2+ in 95.5%.
HPV testing was made preoperatively on 159 patients
(63.3%) and 150 (94.3%) tested positive. In 234 cases of
histology confirmed CIN 1+ lesions the initial HPV test
was made in 142 cases; 137 tested positive, while 3.5%
tested negative (CIN 1 in 2 cases, CIN 3 in 2 cases, and 1
case of microinvasive carcinoma).
At least one post-treatment visit with control cytology
was attended by 217 patients (86.5%). The first control
cytology was taken 4–6 months after surgical procedure
and was abnormal in 45 (20.7%) patients including 21
ASCUS, 1 AGC, 8 ASC-H, 4 LSIL and 11 HSIL. In the
subsequent follow-up period, abnormal cytology was found
in 33 (15.2%) patients including 12 ASCUS, 7 ASC-H, 3
LSIL and 11 HSIL (1 case of HSIL/VAIN 2).
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Analysing the women’s compliance to the post-treat-
ment visits, the complete follow-up control cytology, with
at least three Pap smears in two years or with second
treatment, was performed on only 146 patients (58.2%).
The HPV test was performed on 159 of 217 women
(73%) who attended the post-treatment visits and re-
sulted positive in 25 cases (15.7%). In 6 patients the HPV
test was positive with negative cytology in the two-year
follow-up.
The resection margins were involved in 48 (20.5%) of
234 histologically confirmed CIN1+ lesion with subse-
quent abnormal control cytology in 12 (25%) cases. In 24
(10.3%) cases the margins were difficult to determine
and in 162 (69.2%) the margins were negative with ab-
normal control cytology in 5 (20.5%) cases and 16 (9.9%)
cases respectively. The correlation of resection margins
status with abnormal control cytology findings and posi-
tive histology in the second surgical treatment are shown
in Table 2.
After the first surgical treatment, 24/251 (9.6%) pa-
tients underwent second treatment by biopsy of vagina
(N=1), LLETZ (N=1), conisation (N=11) or hysterec-
tomy (N=11) for abnormal control cytology and also for
non-cervical neoplasia reasons. In the second treatment,
14/217 (6.5%) who attended follow-up visits showed re-
sidual or recurrent disease. In the first treatment, 1 pa-
tient had negative LLETZ, while all other patients had
CIN2+ lesion. The treatment failure was found more of-
ten with positive resection margins (10/48 cases, 20.5%)
compared with the cases when margins were difficult to
determine (2/24 cases, 8.3%) or negative (2/162 cases,
1.2%) Table 3 demonstrates resection margins status,
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TABLE 1
THE INITIAL CYTOLOGY AND CYTOLOGY-HISTOLOGY CORRELATION
Cytology Histology
Neg CIN 1 CIN2/3 CIN3 +AIS AIS MIC +AIS MIC Carcinoma
ASCUS 3 4
ASC-H 1 1 9 1
LSIL 2
HSIL 9 11 153 16
HSIL/could not exclude microinvasion 10 6 1
HSIL/CIN3+AGC 3 1 1 1
HSIL/CIN3+AIS 1 1
AIS 1
Carcinoma 1 1 2 2
Negative 1
Prior biopsy or unknown cytology 4 1 3
CIN – cervical intraepithelial neoplasia, ASCUS – atypical squamous cells of undetermined significance, ASC-H – atypical squamous
cells, cannot exclude HSIL, LSIL – low grade squamous intraepithelial lesion, HSIL – high grade squamous intraepithelial lesion, AGC
– atypical glandular cells, AIS – adenocarcinoma in situ, MIC – microinvasive carcinoma
TABLE 2
THE CORRELATION OF RESECTION MARGINS STATUS WITH
ABNORMAL CYTOLOGY FINDING AND POSITIVE HISTOLOGY

























Total 234 33 14
*percentage of abnormal control cytology and positive histology
after second treatment comparing with resection margins
TABLE 3
RESECTION MARGINS STATUS, CERVICAL CYTOLOGY AND HPV
TEST IN FOLLOW-UP IN PATIENTS WITH AND WITHOUT





– negative 1 2
– positive 7 10
– uncertain 2 2
Cytology
– negative 2 –
– abnormal 2 7
HPV test
– negative – 1
– positive 2 5
*patients who underwent second treatment also for non-cervical
neoplasia reasons
control cytology and the HPV test results in the patients’
follow-up with and without treatment failure in the sec-
ond treatment.
The average period to histology confirmed residual or
recurrent disease was 10 months (min 1, max 35 mon-
ths). In the group of patients with treatment failure in 7
cases there was no repeated cytology and in 7 women the
follow-up smear showed HSIL. In 6 women the control
HPV test was performed; in 5 cases it was positive and in
1 case with VAIN2, it was negative. The characteristics of
women with treatment failure are shown in Table 4.
Discussion
The sensitivity and specificity of the conventional cer-
vical smear cytology are not known precisely but evi-
dence of effectiveness is accepted from observational
studies11. Current Croatian guidelines for management
of premalignant cervical lesions confirm the important
role of cervical cytology12. Our study compared initial
cervical cytology with histology verification of cervical
intraepithelial lesions on conisations or LLETZ and found
high cytology-histology correlation (97.9% for CIN 1+ le-
sions and 95.5% for CIN 2+) with only 13/251 cases with
negative histological findings. Within this group, preop-
erative HPV testing was positive in 7 of 11 patients
(64%) where the HPV test was performed. Analysing
cases with disagreement of cytology with histology 2
cases where found where surface epithelium was de-
tected on the histology specimen with no possibility of
detection of intraepithelial lesion, 1 case of atypical squa-
mous metaplasia and 1 case of microglandular meta-
plasia on histology specimen. In 1 case of second treat-
ment with biopsy of the vagina VAIN 2 was diagnosed on
histology. In all other cases, initial cytology was con-
firmed upon revision of cytologyc specimens by two cytol-
ogists and the disagreement could be explained with
sampling problems for the histology analysis. The dis-
agreement was found more often on LLETZ specimens
(in 7 cases) than on conisation with cold knife (in 4
cases).
Preoperative HPV testing was performed on 63.3% of
treated patients with a 97.8% positive results if only
histologically confirmed CIN2+ lesions were included.
These results are similar to review of Paraskevaidis et al.
of 873 patients treated for high grade CIN with positivity
of 98.3%13. Aerssens et al. reported 11% of negative HPV
test in patients treated for CIN 2/314, while in our study
HPV test was negative in 3.5% of histology confirmed
CIN1+ lesions indicating the high sensitivity of the test
in our material.
Resection margins status was analysed in many stud-
ies as a risk factor for residual disease. Soutter et al.
found that evaluation of the excision margin status does
not reliably predict residual or persistent disease5. Eji-
sink et al. reported that patients with involved excision
margins had a three times higher overall risk of develop-
ing a subsequent HSIL15. They reported positive resec-
tion margins in 19.6% after conisation or LLETZ and in
19.2% margins were difficult to determine. Our results
indicate similar percentage of positive margins (20.5%),
while lower finding of uncertain margins (10.3%), may be
due to greater proportion of cold knife conisations. We
found abnormal control cytology and treatment failure
in greater proportion when margins were positive (25%
and 20.8% respectively) or difficult to determine (20.8%
and 8.3% respectively) compared to the findings with
negative resection margins (9.9% and 1.2% respectively).
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TABLE 4
CHARACTERISTICS OF WOMEN WITH TREATMENT FAILURE
Case Age First treatment Histology Cone margins Pap smear HPV test Time (months) Second treatment Histology
1. 45 conisation MIC + X X 2 hysterectomy Cancer
2. 45 conisation Cancer + X X 2 hysterectomy Cancer
3. 38 conisation CIN 3 + HSIL + 10 LLETZ CIN 2
4. 30 conisation CIN 3 – HSIL + 24 conisation CIN 2
5. 38 conisation MIC + X X 1 conisation CIN 3
6. 35 conisation MIC + X + 2 hysterectomy CIN 3
7. 38 LLETZ CIN 3 + X X 3 conisation CIN 1
8. 40 LLETZ CIN 3 + X X 2 conisation CIN 2
9. 47 LLETZ CIN 2 + X + 25 conisation CIN 2
10. 63 LLETZ CIN 3 susp. HSIL + 20 hysterectomy CIN 2
11. 42 LLETZ CIN 3 susp. HSIL X 8 conisation CIN 3
12. 48 LLETZ negative _ HSIL/VAIN2 – 35 biopsy VAIN 2
13. 34 LLETZ CIN 3 + HSIL X 6 conisation CIN 3
14. 38 LLETZ CIN + HSIL X 5 conisation MIC
CIN – cervical intraepithelial neoplasia, HSIL – high grade squamous intraepithelial lesion, VAIN – vaginal intraepithelial neoplasia,
MIC – microinvasive carcinoma, X – the test was not performed
This study showed that 13.5% of the women did not
attend the follow-up controls in two-year post-treatment
period. Chew et al. reported 12% default to regular cyto-
logical controls in at least seven years of the follow-up pe-
riod at the regional laboratory7. Eijsink et al. reported a
decline in compliance to the follow-up protocol from
86.2% for first to 64.8% for second cervical smears, while
only 51.2% of the patients treated for HSIL with LLETZ
completed the total follow-up program in the first two
years15. Our study showed that the complete follow-up
control cytology with at least three Pap smears in two
years or with second treatment was followed only by 146
patients (58.2%) indicating the need of informing and ed-
ucating the patients about their disease and importance
of post-treatment controls.
This study showed the HPV test was performed in
73.3% patients who attended the post-treatment visits,
but test were not always taken at the first visit (4–6
months after treatment). The used HPV assay does not
differentiate between specific HPV types and we cannot
exclude a possible role of reinfection. This indicates the
need of improvement in the use of the HPV test with its
advantage in early prediction of treatment failure, and in
the cases of negative HPV test to shorten the follow-up
period after treatment of CIN. In our study 6 women had
positive post-treatment HPV test with normal cytology
in two-year follow-up period indicating a need for close
controls for these patients. According to other studies,
persistent post-treatment high-risk HPV is a risk factor
for subsequent CIN16,17 and these patients should un-
dergo colposcopy and close follow-up13.
In the present study out of 217 women who attended
to at least one post-treatment control, abnormal control
cytology was found in 33 (15.2%) cases and treatment
failure occurred in 14 (6.5%) patients. Failure of treat-
ment for CIN 3 has been reported to vary between 5 and
25%, but in our study not all women attended the post-
-treatment visits. We found that the median period to
histology confirmed treatment failure was 10 months,
and in 12/14 (85.7%) the second treatment was per-
formed within two years. Chew et al. reported 9% further
treatment in long term follow-up period, 52% of those
within the first year from the treatment, 19% within the
second year, 4% in the third, 5% in the fourth and fifth
years, and 15% over the next five years. They found no
recurrent lesions after ten years7.
According to the current guidelines, women treated
for CIN are followed for at least 2 years after treatment.
The prolonged follow-up is recommended because late
reoccurrences have been reported5,7,18 what is in accor-
dance with our daily work experience. Chew et al. recom-
mended the need of annual follow-up for 10 years to re-
duce the risk of post-treatment invasive disease7.
Many authors confirm the advantages of combined
cytology and HPV testing14,18–20. The American Society
for Colposcopy and Cervical Pathology (ASCCP) sug-
gested repeat cytology at 4–6 month intervals for up to 2
years and yearly thereafter with HPV testing at 12
months after treatment18. Nobbenhius et al.20 and Zielin-
ski et al.19 recommended monitoring women 6 months af-
ter initial treatment both by cervical cytology and HPV
testing and retesting after 24 months, to avoid missing
cervical carcinomas because of detection problems. If
both tests are negative at 24 months, they referred to
routine screening program.
Conclusion
This study confirms the importance of cervical cytol-
ogy in diagnosis of cervical intraepithelial lesions and
monitoring after treatment. In the future we have to im-
prove compliance to the follow-up protocols and reach an
optimal follow-up algorithm with cytology and HPV test-
ing for detection of women at risk of treatment failure
that will reduce the risk of invasive cancer following con-
servative surgical therapy for CIN.
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CERVIKALNA CITOLOGIJA I HPV TEST U PRA]ENJU PACIJENTICA NAKON KONIZACIJE I
LLETZ-A
S A @ E T A K
Pacijentice lije~ene konzervativnom kirur{kom terapijom radi cervikalne intraepitelne neoplaziije (CIN) imaju po-
ve}ani rizik za razvoj invazivnog karcinoma vrata maternice. Cervikalna citologija i HPV test su metode uklju~ene u
postupnike za otkrivanje neuspjeha lije~enja. Cilj rada je analiza citolo{ko-histolo{ke korelacije nakon konizacije ili
ekscizije transformacijske zone pomo}u dijatermijske om~e (LLETZ), analiza resekcijskih rubova ekscizata, analiza
odaziva pacijentica na protokol pra}enja te evaluacija cervikalne citologije i HPV testa u dvogodi{njem pra}enju nakon
lije~enja. Retrospektivnom analizom 251 zahvata konizacije (N=141) i LLETZ-a (N=110) u~injenih izme|u sije~nja i
prosinca 2006. godine, obra|eni su rezultati nalaza konvencionalnih citolo{kih uzoraka i digene Hybrid capture II testa
za detekciju 13 visoko-rizi~nih HPV tipova. Histolo{kom analizom na|ena je CIN 1+ lezija u 234 slu~aja (93,2%), s
citolo{ko-histolo{kom korelacijom od 97,9%. Preoperativni HPV test ra|en je u 142 slu~aja histolo{ki potvr|ene CIN
1+ lezije i u 137 slu~ajeva (96,5%) je bio pozitivan. Resekcijski rubovi bili su pozitivni u 48 slu~aja (20,5%) a u 24 slu~aja
(10,3%) rubovi se nisu mogli procijeniti. Abnormalna kontrolna citologija na|ena je u 33 (15,2%) od 217 pacijentica koje
su pristupile kontroli nakon lije~enja. Kontroni HPV test bio je pozitivan u 25/159 (15,7%) slu~aja. Potpuno pra}enje s
barem tri Papa testa u dvije godine ili s drugim kirur{kim zahvatom na|eno je u samo 146 (58,2%) pacijentica. Kod 14
(6,5%) pacijentica pri drugom kirur{kom zahvatu histolo{ki je dokazan neuspjeh lije~enja. Kod onih pacijentica kod
kojih je u~injena kontrolna citologija na|ena je skvamozna intraepitelna lezija visokog stupnja. U {est `ena ra|en je
kontroni HPV test, u pet slu~ajeva bio je pozitivan dok je u slu~aju histolo{ki potvr|ene vaginalne intraepitelne lezije
(VAIN2) na biopsiji nalaz bio negativan. Na{i rezultati potvr|uju va`nost cervikalne citologije u dijagnostici cervikalnih
intraepitelnih lezija i pra}enju nakon lije~enja. U budu}nosti moramo pobolj{ati odaziv `ena na kontrolne preglede
nakon zahvata kao i kori{tenje HPV testa za otkrivanje pacijentica s rizikom od neuspje{nog lije~enja.
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